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Context: The two major forms of circulating thyroid hormones (THs) are tri-iodothyronine (T3) 38 
and tetra-iodothyronine (T4). T3 is regarded as the biologically active hormone since it binds to 39 
thyroid hormone receptors (TRs) with greater affinity than T4. However, it is currently unclear 40 
what structural mechanisms underlie this difference in affinity. 41 
Objective: Prompted by the identification of a novel M256T mutation in a resistance to thyroid 42 
hormone alpha (RTHα) patient, we investigated Met256 in TRα1 and the corresponding residue 43 
(Met310) in TRβ1, residues previously predicted by crystallographic studies in discrimination of 44 
T3 versus T4.   45 
Methods: Clinical characterization of the RTHα patient and molecular studies (in silico protein 46 
modeling, radioligand binding, transactivation and receptor-cofactor studies) were performed. 47 
Results: Structural modeling of the TRα1-M256T mutant showed that distortion of the 48 
hydrophobic niche to accommodate the outer ring of ligand was more pronounced for T3 than 49 
T4, suggesting that this substitution has little impact on the affinity for T4. In agreement with the 50 
model, TRα1-M256T selectively reduced the affinity for T3. Also, unlike other naturally 51 
occurring TRα mutations, TRα1-M256T had a differential impact on T3- versus T4-dependent 52 
transcriptional activation. TRα1-M256A and TRβ1-M310T mutants exhibited similar 53 
discordance for T3 versus T4.  54 
Conclusions: Met256-TRα1/Met310-TRβ1 strongly potentiates the affinity of TRs for T3, 55 
thereby largely determining that T3 is the bioactive hormone rather than T4. These observations 56 
provide insight into the molecular basis for underlying the different affinity of TRs for T3 versus 57 
T4, delineating a fundamental principle of thyroid hormone signaling. 58 
  59 
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Précis 60 
Met256-TRα1/Met310-TRβ1 determine the differential bioactivity of T3 versus T4, providing the 61 





Thyroid hormones (THs) are indispensable for normal growth, development, and 66 
metabolism. The two major forms of TH (tri-iodothyronine [T3] and tetra-iodothyronine 67 
[thyroxine, T4]) exist. In 1952, it was recognized that T3 has greater biological potency than T4 68 
(1-4). This fundamental discovery led to the clinical concept that T4, despite being the most 69 
abundant circulating iodothyronine, functions as a prohormone, with T3 being the biologically 70 
active hormone. Since then, this paradigm has remained unchanged, although the molecular and 71 
structural mechanisms underlying this have not been investigated in detail. 72 
The genomic actions of THs are exerted through binding to the three functional isoforms 73 
of thyroid hormone receptors (TRs), namely TRα1, TRβ1, and TRβ2, which are highly 74 
homologous but have distinctive expression patterns (5-7). Mutations in TRα and TRβ give rise 75 
to clinically distinct syndromes in humans, termed resistance to thyroid hormone (RTH) α and β, 76 
respectively (8-14). RTHβ patients commonly present with goiter and tachycardia with abnormal 77 
thyroid function tests (TFTs), including high serum (F)T3 and (F)T4 concentrations with normal 78 
or slightly increased TSH concentrations. The clinical phenotype of RTHα is distinct from RTHβ 79 
and includes growth retardation, macrocephaly, constipation, intellectual disability, and anemia. 80 
In RTH, TFTs are typically characterized by high to high-normal (F)T3, low to low-normal 81 
(F)T4, low rT3 and normal TSH concentrations. 82 
The greater biological activity of T3 versus T4 is explained by differences in affinity for 83 
the functional isoforms of thyroid hormone receptors (TRs). The binding affinity of T4 to the 84 
TRs is 10 to 30-fold less compared with T3 (15-17). Previous crystallographic studies revealed 85 
that the ligand-binding pocket of TRβ1 is able to accommodate both T3 and T4, although the 86 
H11-H12 loop is more loosely packed in the presence of T4 than T3 (16). These structural 87 
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adaptations of TRβ1 which are required to accommodate the larger T4 molecule have been 88 
attributed to possible steric hindrance of its bulky 5’-iodine moiety with surrounding amino acids, 89 
especially the Met residue located at position 310 in TRβ1. Although no co-crystallization studies 90 
of TRα with T4 are available, a similar role for Met256 in TRα (equivalent position of Met310 in 91 
TRβ), has been suggested (18). However, no functional studies, to support the relevance of these 92 
residues for the differences in affinity for T3 and T4, have been performed.  93 
Therefore, we here combined structural modeling and in vitro approaches to determine the 94 
differential role of these Met residues in T3 versus T4 binding by TRs, and also characterized a 95 
newly-identified TRα1-M256T and previously published TRβ1-M310T mutations, which 96 
naturally occur in patients with RTH (19-21). We showed that these Met residues are of 97 
particular importance for the binding of T3, and not T4. This observation provides the underlying 98 
molecular and structural basis for the role of T4 as prohormone and T3 as bioactive hormone in a 99 
paradigm for TH physiology and daily clinical practice. 100 
  101 
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Materials and Methods 102 
 103 
TRα-M256T identification 104 
 The TRα-M256T mutation in an RTHα patient was identified by exome sequencing and 105 
was confirmed by Sanger sequencing as previously described (12) after obtaining an inform 106 
consent. This study was conducted following the Declaration of Helsinki principles and was  107 
approved by the Medical Ethical Committee of the Erasmus Medical Center, Rotterdam, The 108 
Netherlands (MEC-2015-362). 109 
In silico prediction of TRα1-M256T function 110 
The TRα1-M256T mutation bound to T3 and T4 were modeled into the wild-type (WT) 111 
TRα1 crystal structure (PDB-ID: 2H77 (22)), and the M256T and M256A mutations were 112 
introduced using the side-chain substitution tool of the YASARA Structure Software (YASARA 113 
Bioscience GmbH, Vienna, Austria) (23) and processed as previously described (24).  114 
DNA constructs and mutagenesis 115 
The pcDNA3 FLAG-TRα1 and TRβ1 expression vectors containing full-length human 116 
TRα1 and TRβ1 with 5’ FLAG-tagged (11,24) and the pCMX VP16-TRα1 expression vector 117 
containing full-length human TRα1 fused with VP16 (25) have been described previously. The 118 
TRα1-M256T, TRβ1-M310T, as well as the other TRα1 mutations (M256A, A263S, D211G, and 119 
R384H) were introduced, using the QuickChange II Mutagenesis kit (Agilent Technologies, 120 
Amstelveen, The Netherlands) according to the manufacturers’ protocol. The introduced 121 
mutations were confirmed by Sanger sequencing. 122 
Radioligand competitive binding assays 123 
FLAG-TRα1 WT, M256T, and M256A receptor proteins were synthesized using the 124 
TnT® T7 Quick Coupled Transcription/Translation System (Promega, Leiden, The Netherlands). 125 
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The affinity for T3 and T4 of the receptors was determined by competitive binding assays as 126 
previously described (24) using [125I]T3 and [125I]T4, respectively. The dissociation constant 127 
(Kd) was analysed by GraphPad Prism program version 5.0 (GraphPad, La Jolla, CA) and shown 128 
as a mean ± standard error of the mean (SEM) of three independent experiments performed in 129 
duplicate. 130 
Cell culture and transfection 131 
JEG-3 cells (ECACC Cat# 92120308, RRID:CVCL_0363, Sigma-Aldrich) were cultured 132 
and transfected as previously described (24,26). Given the absence of 5’-deiodinating activity in 133 
this cell-type (27), there is no intracellular deiodination of T4 to T3, which allowed us to study 134 
the direct effect of T3 and T4 on transactivation. For transcriptional activity assays, WT or 135 
mutant receptors were co-expressed with luciferase reporter constructs containing direct repeat 136 
thyroid hormone response elements (DR4-TRE) as well as pMaxGFP as a transfection control. 137 
We also co-expressed WT and TRα1-M256T in 1:1 equimolar ratio to determine the effect of the 138 
mutant on WT function (dominant-negative effect). For receptor-cofactor interaction (two-139 
hybrid) assays, VP16-fused WT or TRα1-M256T were co-expressed with a luciferase reporter 140 
construct containing Gal4 binding site (UAStkLuc), together with pSG424 expression vectors 141 
containing the Gal4DBD fused to the interacting domains of NCoR1 or SRC1 (11). After 24 142 
hours transfection, cells were stimulated with 0-10,000 nM T3 (Cat. No. T2877, Sigma-Aldrich) 143 
or T4 (Cat. No. T2376, Sigma-Aldrich) in DMEM/F12 medium supplemented with 0.1% bovine 144 
serum albumin for 24 hours. 145 
Immunoblotting 146 
The expression of FLAG-tagged and VP16-fused receptors in JEG-3 cells was verified by 147 
immunoblotting nuclear extracts as previously described (24,26). FLAG-tagged TRα1 and VP16-148 
TRα1 were detected with a 1:1000 dilution of FLAG-M2 (#F1804 Sigma-Aldrich) and VP16 (sc-149 
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7545, Santa Cruz Biotechnology) antibodies. The Histone 3 protein was detected as loading 150 
control with a 1:1000 dilution of a Histone 3 antibody (H3; 1B1B2) (#14269 Cell Signaling 151 
Technology).  152 
Luciferase assays 153 
 Luciferase activity was measured as previously described (12,24). Data were expressed as 154 
percentage maximal response of WT stimulated by T3. Half-maximal effective concentration 155 
(EC50), half-maximal inhibitory concentration (IC50), and maximal response were calculated 156 
using GraphPad Prism program version 5.0 (GraphPad, La Jolla, CA). The results are shown as a 157 
mean ± SEM of at least three independent experiments performed in triplicate. 158 
Statistical analysis 159 
 Statistical differences of logKd, logIC50, and logEC50 values between groups were 160 
analyzed by student’s t-test or one-way ANOVA with Tukey’s post-test. The percentage maximal 161 
response of mutants was compared to WT by one sample t-test. Statistical significance was 162 
considered when p-values < 0.05. 163 




Clinical characterization 166 
A de novo heterozygous missense mutation in the THRA gene (c.767T>C), resulting in 167 
substitution of Thr for Met at codon 256 (p.M256T), was identified in a 19-year-old male 168 
presenting with features similar to previously reported RTHα patients, including disproportionate 169 
ischial leg length (sitting height to height ratio +2.5 SDS), mild neurodevelopmental delay, 170 
coarse facies, macrocephaly (head circumference 60 cm, +2.5 SDS), and high serum T3/T4 ratio 171 
with normal TSH concentrations (FT4 10.6 pmol/L [normal range, N 11-25], total T4 67 nmol/L 172 
[N 58-128], total T3 2.9 nmol/L [N 1.4-2.5], reverse T3 0.18 nmol/L [N 0.22-0.54], T3/T4 ratio 173 
0.043 [N 0.01-0.03], and TSH 1.83 mU/L [N 0.4-4.3]) (Fig. 1). This mutation is not present in 174 
public databases (dbSNP, 1000Genome, and Exome Aggregation Consortium [ExAC]). 175 
Protein modeling 176 
The role of the Met256 in TRα1 function and potential effect of this mutation on the 177 
affinity of both T3 and T4 was first predicted by in silico modeling. Given the absence of a T4-178 
bound TRα crystal structure, we first studied the structural organization of the domains 179 
surrounding the outer ring of TH in the available T3- (PDB ID: 1xzx) and T4-liganded (PDB ID: 180 
1y0x) crystal structures of TRβ1. In line with a previous report (16), we observed that the 5’ 181 
position of the outer ring of both T3 and T4 is flanked by Ile276 (helix [H] 3), Met310 and 182 
Met313 (H6), His435 (H11), Phe455 and Phe459 (H12) of TRβ1. Together, these residues form a 183 
niche that allows the accommodation of T4 despite the presence of its bulky 5’-iodine. The same 184 
niche is also present within the T3-liganded TRβ1 crystal, but is considerably smaller in the 185 
absence of the 5’-iodine. Met310 (corresponding to Met256 of TRα1) is located in closest 186 
structural proximity to the 5’ carbon of the outer ring and moreover forms an extensive network 187 
of (hydrophobic) interactions that link H6, H11 and H12. 188 
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We next modeled a T4 molecule into the ligand binding pocket of the available T3-189 
liganded TRα1 crystal structure (PDB-ID: 2H77) (Fig. 2b). Compared to the T3-liganded TRα1 190 
structure (Fig. 2a), a slight outward shift of H11 and H12 was observed in the T4-liganded 191 
model, which was accompanied by re-orientation of side-chains of residues surrounding the 5’ 192 
iodine. Amongst others, this resulted in a loss of the direct hydrophobic interactions between 193 
Met256 and the outer ring and a less tightly packed structural organization of the ligand binding 194 
pocket. These changes were similar to those observed in the corresponding TRβ1 crystal 195 
structures, validating the accuracy of the modeling procedure.  196 
We subsequently modeled the M256T (shortening of side-chain, hydrophilic moiety) 197 
mutant in both T3- and T4-bound TRα1 structures and analyzed the impact on the conformation 198 
of the ligand binding domain and direct substrate interactions (Fig. 2c-d). The artificial M256A 199 
mutant was also modeled in order to reduce the side-chain length but maintain the hydrophobic 200 
property of the residue (Fig. 2e-f). Due to shortening of side-chain length in both mutants, direct 201 
hydrophobic interaction with the outer ring of T3 was lost (Fig. 2c and e). Moreover, both 202 
mutants enlarged the niche surrounding the 5’ position of T3 due to re-orientation of various 203 
residue side-chains in H11 and H12 and the subsequent outward shift of these helices. As a result, 204 
the niche adopts a structural configuration that resembles the WT receptor in T4-bound state. 205 
These changes were more pronounced for the M256T than the M256A, exemplified by the degree 206 
of re-orientation of His381, previously implicated in interact with the phenolhydroxyl group of 207 
T3 (18) (Fig. 2g). In the case of T4, both mutations had little effect on structural organization 208 
(Fig. 2d, f, and h). Based on these in silico predictions, we therefore hypothesized that both 209 
substitutions would have a greater impact on T3 than on T4 binding and action. 210 
Functional studies 211 
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Next, we performed in vitro studies to test this hypothesis. In line with previous literature 212 
(15-17), competitive binding assays showed that the affinity for T4 of WT TRα1 was ~7-fold 213 
lower than for T3, indicated by a higher Kd of T4 than T3 (Fig. 3a and Table 1). The TRα1-214 
M256T mutant showed a ~40-fold lower T3 binding affinity than WT, whereas T4 affinity was 215 
unchanged (Fig. 3c and Table 1). Also, the binding affinity of the TRα1-M256A mutant for T3 216 
was selectively reduced (~6-fold) (Fig. 3e and Table 1).  217 
To evaluate the impact of both mutations on the transcriptional activity, WT and mutant 218 
receptors were co-transfected with a reporter construct in which luciferase expression is under 219 
control of a thyroid hormone response element (TRE) into JEG-3 cells with increasing 220 
concentrations of T3 or T4. Equal expression of WT and both mutants was confirmed by 221 
immunoblotting nuclear extracts with anti-FLAG antibodies (Fig. 3b). In line with the binding 222 
assays and previous studies (16,17), the transcriptional activation assay showed that the EC50 of 223 
WT TRα1 induced by T4 was approximately 60-fold higher than that induced by T3 (Fig. 3b and 224 
Table 1). The EC50 of TRα1-M256T was 100-fold higher for T3 but unchanged for T4 compared 225 
to WT (Fig. 3d and Table 1). The TRα1-M256A also selectively reduced transcriptional activity 226 
induced by T3 (Fig. 3f and Table 1). The transcriptional activity was also reduced when WT and 227 
TRα1-M256T were co-expressed compared to WT expressed alone, suggesting a dominant-228 
negative effect of this mutant (data not shown). In mammalian two-hybrid assays compared to 229 
WT, the TRα1-M256T mutant also affected ligand-dependent interactions with the corepressor 230 
NCoR1 (fold increase IC50: ~80-fold for T3 and ~6-fold for T4) and the coactivator SRC1 (fold 231 
increase EC50: ~90-fold for T3 and ~6-fold for T4) (Fig. 4a-d and Table1). Together, our results 232 
indicate that the mutations located at the Met256 of TRα1 have a differential impact on the 233 
binding and activation of the receptor by T4 versus T3.  234 
13 
We next investigated if this T3 versus T4 difference is also present in other TRα mutants 235 
located outside the niche surrounding the 5’-iodine position. However, these naturally occurring 236 
mutations (D211G, A263S, and R384H) had a similar impact on both T3 and T4 induced 237 
transactivation, and, as for WT TRα, the EC50 values for T4 exceeded those for T3 by ~30-50-238 
fold (Fig. 5a-c). These transcriptional activation profiles were in contrast to the M256T mutant 239 
(Fig. 5d), strongly indicating that only this mutant has a predominant impact on T3 affinity. To 240 
extend our findings to TRβ, we also studied the transcriptional activity of a corresponding 241 
mutation in TRβ1 (TRβ1-M310T). The EC50 of WT TRβ1 induced by T4 was ~70-fold higher 242 
than that induced by T3 (Fig. 6a), which was similar to WT TRα1. The T3-induced 243 
transcriptional response of TRβ-M310T was greatly reduced, which contrasted with the T4-244 






Although the notion of T4 and T3 being the precursor and active hormone respectively, is 249 
widely recognized in both the clinical and scientific community, the molecular and structural 250 
basis of this dogma has received little attention. In this study, we highlight the crucial role of 251 
residue Met256 of TRα1 and Met310 of TRβ1 in determining the differential bioactivity of T3 252 
versus T4, using a novel mutant (TRα1-M256T) identified in an RTHα patient and a mutant at 253 
the corresponding position (TRβ1-M310T) identified in RTHβ patients (19-21). In contrast to 254 
WT TRα or TRβ and mutations involving other residues, mutations at these Met residues 255 
selectively affected binding and transactivation of TR by T3. These observations emphasize the 256 
key role of these residues in designating T4 as the prohormone and T3 as the major bioactive 257 
hormone. 258 
In line with previous reports (15-17), our results showed that T3 has a higher binding 259 
affinity for WT TRα1 and stimulates receptor activity with a higher potency than T4. Previous 260 
structural studies in TRβ1 have suggested that the lower affinity for T4 is caused by decreased 261 
packing of the ligand binding domain in presence of T4 versus T3, which particularly allows 262 
oscillation of H12 between liganded and unliganded states resulting in a higher ligand 263 
dissociation rate (16). Here, we extend these observations by showing that the ligand binding 264 
domain of T3-liganded TR has a similar decrease in packing as observed in T4-liganded WT 265 
receptors upon substitution of Met256 in TRα1 or Met310 in TRβ1 by Thr. In contrast, these 266 
substitutions hardly changed the predicted structure of T4-liganded mutant receptors. Based on 267 
these models, we postulated that the extensive (hydrophobic) interactions of Met with 268 
surrounding residues are key in stabilizing inter-helical interactions (e.g. between H6, H11 and 269 
H12), which facilitate the tight packing of the ligand binding domain as observed in T3-liganded 270 
receptors. Moreover, we observed a direct interaction between Met and the 5’ position of the 271 
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outer ring of T3, which was not formed with T4. This suggests that Met256 in TRα1 and Met310 272 
in TRβ1 have a critical role in achieving optimal folding and enthalpy in T3-liganded receptors, 273 
whereas their role in T4 binding is of less importance. 274 
This in silico prediction was confirmed by in vitro studies indicating that TRα1-M256T 275 
selectively affected binding affinity for T3, and cofactor interactions and transcriptional activity, 276 
of T3-stimulated receptor. These properties seemed specific for the M256T mutant as the 277 
transactivation potency of T3 and T4 with TRα mutants identified in other RTHα patients 278 
(D211G (26), A263S, and R384H (28)) was affected equally. Additional testing of the naturally 279 
occurring mutation at the corresponding residue in the TRβ1 (M310T) (19-21) further 280 
substantiated the specificity of the findings. 281 
Since Thr substitution at position 256 in TRα1 or 310 in TRβ1 not only alters the binding 282 
space but also affects the hydrophobicity of the ligand-binding pocket, we also tested the artificial 283 
TRα1-M256A mutant, which reduces the size of the side-chain but maintains the hydrophobic 284 
property of the ligand-binding pocket. Indeed, functional studies showed that TRα1-M256A also 285 
selectively impairs T3 binding affinity and T3-induced transcriptional activity, while T4 binding 286 
and activity are maintained. Although the effect of TRα1-M256T mutation in our functional and 287 
structural models was slightly greater than that of TRα1-M256A, these findings support the 288 
notion that loss of the specific properties of Met, rather than the unfavorable impact of the 289 
hydrophilic moiety of Thr on the hydrophobic environment, are mainly responsible for the 290 
differential impact on T3 versus T4 signaling. Based on our studies and a previous report (16), 291 
we propose that Met256 in TRα1 and Met310 in TRβ1 are crucial residues that determine 292 
specific affinity for T3 versus T4. Thr and Ala substitution at these Met positions significantly 293 
affected the hydrophobic interactions with T3 and altered the niche accommodating the outer ring 294 
of T3 to a “T4-bound” configuration, both resulting in a reduced binding affinity of the mutants 295 
16 
for T3. In contrast, since the ligand binding domain of T4-liganded receptors already exhibit 296 
looser packing without direct interaction(s) between Met and the T4 molecule, mutations in the 297 
Met residue are better tolerated. 298 
No unique phenotype was discernible in the newly-identified M256T RTHα patient when 299 
compared to other cases of RTHα harbouring missense mutations in the THRA gene (25,26,28-300 
30), or in patients carrying TRβ-M310T (19-21) when compared to other RTHβ cases reported in 301 
the literature. These findings indicate that although mutations at Met256-TRα1/Met310-TRβ1 302 
residues preserve T4 binding to mutant receptor proteins, this property is not sufficient to prevent 303 
patients from developing features of RTH, implying that the phenotype of RTH is linked 304 
primarily to defective T3 rather than T4 binding by mutant TRs. 305 
To our knowledge, this is the first study that provides in vitro evidence for the importance 306 
of Met256 in TRα1 and Met310 in TRβ1 in ligand recognition. Our studies highlight the 307 
relevance of this Met residue in TRs for discrimination between T3 and T4, providing the 308 
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Legends for Figures and Table 415 
 416 
Table 1. Summary of the results of competitive binding, transcriptional activity, and protein-417 
protein interaction assays of WT, TRα1-M256T and TRα1-M256A mutants. 418 
 419 
Figure 1. (a) Pedigree chart demonstrating that only the index patient (II.1) has the clinical 420 
phenotype of RTHα. (b) Sequence analysis of exon 8 of THRA gene shows a de novo 421 
heterozygous missense mutation (c.767T>C) in index patient, resulting in a Met to Thr 422 
substitution at codon 256 (p.M256T). 423 
 424 
Figure 2. Comparison of the architecture of the TRα1 ligand binding pocket in the presence of 425 
T3 and T4. (a) Close-up view of the ligand-binding pocket of the TRα1 crystal structure in 426 
complex with T3 (PDB ID: 2h77) and (b) with T4. The residue side-chains lining the niche that 427 
accommodates the outer ring of T3 and T4 are highlighted and their molecular surface is shown 428 
except for Phe405 for clarity. The 5’ iodine group of T4 is represented by the green ball in T4-429 
bound TRα1 model. The hydrophobic contacts between Met256 and the phenolic outer ring are 430 
depicted as dashed lines. Structural models of the TRα1-M256T mutant in complex with T3 (c) 431 
and T4 (d). Structural models of the TRα1-M256A mutant in complex with T3 (e) and T4 (f). 432 
Overlay of the structural orientation of the residue side-chains that face the T3 (g) and T4 (h) 433 
ligands at the 5’ position in WT (grey), M256T (blue) and M256A (red) mutant TRα1 models. 434 
All figures were created in YASARA Structure using PovRay imaging software. 435 
 436 
24 
Figure 3. (a, c, e) [125I]T3 dissociation curves showing that compared to (a) WT, the (c) TRα1-437 
M256T mutation and (e) TRα1-M256A mutation reduces the affinity for T3 (solid line) more 438 
than for T4 (dashed line) (mean ± SEM of three experiments for WT and M256T and two 439 
experiments for M256A performed in duplicate). (b, d, f) The TRα1-M256T and TRα1-M256A 440 
mutations also had a larger effect on T3- than on T4-dependent transcriptional activation (mean 441 
± SEM of three experiments performed in triplicate). The effect of the Ala substitution on the 442 
ligand binding affinity and the transcriptional activity of TRα1 was less than the effect of the Thr 443 
substitution. (Insert of b) Immunoblots confirm an equal expression of WT, M256T, and M256A 444 
FLAG-tagged TRα1 and Histone 3 as a loading control in the nuclear fraction of JEG-3 cells. 445 
446 
Figure 4. The TRα1-M256T mutation had a larger effect on T3- than on T4-dependent (a-b) 447 
GAL4-NCoR1 dissociation, and (c-d) GAL4-SRC1 association (mean ± SEM of at least three 448 
experiments performed in triplicate). (Insert of a) Immunoblots confirm an equal expression of 449 
WT and M256T VP16 TRα1 fusion proteins and Histone 3 as loading control in the nuclear 450 
fraction of JEG-3 cells. 451 
452 
Figure 5. (a-c) The T4-induced transcriptional activity of three TRα1 mutations identified in 453 
RTHα patients is lower than that is induced by T3, which is similar to WT (Fig. 2d) (mean ± 454 
SEM of three experiments performed in triplicate). (d) The EC50 of T4 is approximately 30-50 455 
fold higher than the EC50 of T3, except for TRα1-M256T (One-way ANOVA with Tukey’s post-456 
test, ***p<0.001).  457 
458 
25 
Figure 6. The T3- and T4-induced transcriptional activity of (a) WT and (b) TRβ1-M310T in 459 
JEG-3 cells shows that the TRβ1-M310T mutation affects T3- more than T4-dependent 460 
transcriptional activation (mean ± SEM of four experiments performed in triplicate), which is in 461 
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